SMS Lifesciences India Ltd.
Snapshot View

710.55 +1.00 ▲0.1%

30 July 2021, 04:00:00 P.M.
Volume: 545

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.smslife.in
Financial Indicators
Market Cap 213.53 Cr.
Earnings per share (EPS) 44.84 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 15.75 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 427.40 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.65 Calculated using Price: 706.30
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.30 Cr. 3,023,287 Shares
FaceValue 10
Company Profile

SMS Lifesciences is a global player in Active Pharmacy Ingredients (API) manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having product list spreading across an array of therapeutic segments.

The company has two API facilities known as Khazipally unit and Jeedimetla unit. Both these units are located in the Hyderabad. The company aims at achieving Quality excellence and customer satisfaction through Good Manufacturing practices and strives for continual improvement. All its manufacturing facilities are ISO:9001 certified and are WHO-GMP compliant.

SMS Lifesciences has developed fully equipped quality control cells at all the manufacturing facilities manned by experienced and qualified staff. SMS Lifesciences has the required capabilities and infrastructure to ensure full operation of the quality function from Raw material analysis to in process analysis and analysis of final products.

Business area of the company:

SMS Lifesciences India is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.14%
1 Week
-3.45%
1 Month
-7.26%
3 Month
+19.66%
6 Month
+26.67%
1 Year
+114.28%
2 Year
+76.53%
5 Year
2 years 2019-03 2020-03
Return on Equity (%) 16.78 9.17
Return on Capital Employed (%) 20.14 11.91
Return on Assets (%) 6.45 3.83

Balance Sheet View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 106 116
Non Curr. Liab. 39 50
Curr. Liab. 132 90
Minority Int.
Equity & Liab. 276 256
Non Curr. Assets 128 146
Curr. Assets 149 110
Misc. Exp. not W/O
Total Assets 276 256

Profit Loss View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 378 261
Other Income 3 2
Total Income 380 263
Total Expenditure -343 -235
PBIDT 37 28
Interest -6 -5
Depreciation -6 -8
Taxation -8 -4
Exceptional Items
PAT 18 10

Cash Flow View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 30 15
Cash Fr. Inv. -44 -27
Cash Fr. Finan. 15 12
Net Change 1 0
Cash & Cash Eqvt 2 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 67.99 67.99 67.99 68.00 68.00 68.24 68.26 68.26 67.74
Public 32.01 32.01 32.01 32.00 32.00 31.76 31.74 31.74 32.26
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 8.74 8.74 8.74 8.74 8.74 8.71 3.51 3.51 0.00

Announcements View Details

Fri, 16 Jul 2021
Shareholding for the Period Ended June 30 2021
SMS Lifesciences India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 16 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Trupti Ranjan Mohanty
Designation :- Company Secretary and Compliance Officer
Fri, 16 Jul 2021
Consolidated Related Party Transactions [H2-F21]
Disclosure as per Reg. 23 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015

Technical Scans View Details

Fri, 30 Jul 2021
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
+DI Crossing -DI From Above +DI Crossing -DI From Above
Stochastic %K Crossing %D from Below Stochastic %K Crossing %D from Below
Stochastic In Oversold Zone Stochastic In Oversold Zone
Price Nearing SuperTrend Support Price Nearing SuperTrend Support

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%